SK ion-channel inhibitors (AP31969) to treat atrial fibrillation
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Series B Copenhagen biotech Acesion Pharma raised a 45M EUR Series B led by Canaan and Alpha Wave to advance its atrial-fibrillation drug AP31969. | $48.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.